Shaodong Hong

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 16

Top Topics

Systematic Review

Small Cell Lung Cancer

Squamous Cell Carcinoma

Top Venues

Journal for immunotherapy of cancer

Cancer immunology, immunotherapy : CII

Cancer medicine

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Anlin Li, Linfeng Luo, Wei Du, Zhixin Yu, Lina He, Sha Fu, Yuanyuan Wang, Yixin Zhou, Chunlong Yang, Yunpeng Yang, Wenfeng Fang, Li Zhang, Shaodong Hong
Deciphering transcriptomic determinants of the divergent link between PD-L1 and immunotherapy efficacy. NPJ precision oncology 7 (1) (2023)
Zichun Li, Xuanye Zhang, Yuhong Wang, Zhixin Yu, Chunlong Yang, Yixin Zhou, Shaodong Hong
Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy. Journal for immunotherapy of cancer 11 (10) (2023)
Wei Du, Chen Chen, Lin-Feng Luo, Li-Na He, Yixing Wang, Xuanye Zhang, Yixin Zhou, Zuan Lin, Shaodong Hong
Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer. Journal of cancer research and clinical oncology (2022)
Hui Yu, Ping Chen, Liangping Xia, Sha Fu, Chen Chen, Xuanye Zhang, Lina He, Bei Zhang, Yixin Zhou, Shaodong Hong
PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer. Journal for immunotherapy of cancer 9 (11) (2022)
Yuxiang Ma, Xi Chen, Ao Wang, Hongyun Zhao, Qingguang Lin, Hua Bao, Yang Zhang, Shaodong Hong, Wanxiangfu Tang, Yan Huang, Yunpeng Yang, Xue Wu, Yang Shao, Wenfeng Fang, Li Zhang
Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma. Journal for immunotherapy of cancer 9 (3) (2021)
Hui Yu, Ping Chen, Xiuyu Cai, Chen Chen, Xuanye Zhang, Lina He, Yixin Zhou, Shaodong Hong, Bei Zhang
Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer. Cancer immunology, immunotherapy : CII (2021)
Shaodong Hong, Ya-Xiong Zhang, Gengsheng Yu, Peijian Peng, Jiewen Peng, Jun Jia, Xuan Wu, Yan Huang, Yunpeng Yang, Qing Lin, Xuping Xi, Mingjun Xu, Dongping Chen, Xiaojun Lu, Ren-Sheng Wang, Xiaolong Cao, Xiaozhong Chen, Zhixiong Lin, Jianping Xiong, Qin Lin, Conghua Xie, Zhihua Li, Jianji Pan, Jingao Li, Shixiu Wu, Yingni Lian, Quanlie Yang, Chong Zhao, Wenfeng Fang, Li Zhang
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (29) (2021)
Zuan Lin, Xuanye Zhang, Yixin Zhou, Chen Chen, Li-Na He, Haifeng Li, Yuhong Wang, Tao Chen, Shaodong Hong, Li Zhang
Correction to: Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus. Cancer immunology, immunotherapy : CII (2021)
Zuan Lin, Xuanye Zhang, Yixin Zhou, Chen Chen, Li-Na He, Haifeng Li, Yuhong Wang, Tao Chen, Shaodong Hong, Li Zhang
Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus. Cancer immunology, immunotherapy : CII (2021)
Shen Zhao, Zhonghan Zhang, Yaxiong Zhang, Shaodong Hong, Ting Zhou, Yunpeng Yang, Wenfeng Fang, Hongyun Zhao, Li Zhang
Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer. International journal of cancer 144 (11) (2019)
Xuanye Zhang, Yixin Zhou, Chen Chen, Wenfeng Fang, Xiuyu Cai, Xiaoshi Zhang, Ming Zhao, Bei Zhang, Wenqi Jiang, Zuan Lin, Yuxiang Ma, Yunpeng Yang, Yan Huang, Hongyun Zhao, Ruihua Xu, Shaodong Hong, Li Zhang
Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. Journal for immunotherapy of cancer 7 (1) (2019)
Yixin Zhou, Zuan Lin, Xuanye Zhang, Chen Chen, Hongyun Zhao, Shaodong Hong, Li Zhang
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy. Journal for immunotherapy of cancer 7 (1) (2019)
Jiaqing Liu, Hua-Qiang Zhou, Yaxiong Zhang, Yan Huang, Wenfeng Fang, Yunpeng Yang, Shaodong Hong, Gang Chen, Shen Zhao, Xi Chen, Zhonghan Zhang, Jiayi Shen, Wei Xian, Jianhua Zhan, Yuanyuan Zhao, Xue Hou, Yuxiang Ma, Ting Zhou, Hongyun Zhao, Li Zhang
Docosapentaenoic acid and lung cancer risk: A Mendelian randomization study. Cancer medicine 8 (4) (2019)
Yixin Zhou, Chen Chen, Xuanye Zhang, Sha Fu, Cong Xue, Yuxiang Ma, Wenfeng Fang, Yunpeng Yang, Xue Hou, Yan Huang, Hongyun Zhao, Shaodong Hong, Li Zhang
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis. Journal for immunotherapy of cancer 6 (1) (2018)
Zhonghan Zhang, Yaxiong Zhang, Gang Chen, Shaodong Hong, Yunpeng Yang, Wenfeng Fang, Fan Luo, Xi Chen, Yuxiang Ma, Yuanyuan Zhao, Jianhua Zhan, Cong Xue, Xue Hou, Ting Zhou, Shuxiang Ma, Fangfang Gao, Yan Huang, Likun Chen, Ningning Zhou, Hongyun Zhao, Li Zhang
Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis. The oncologist 23 (5) (2018)
Gang Chen, Xi Chen, Yaxiong Zhang, Fang Yan, Wenfeng Fang, Yunpeng Yang, Shaodong Hong, Siyu Miao, Manli Wu, Xiaodan Huang, Youli Luo, Cong Zhou, Run Gong, Yan Huang, Ningning Zhou, Hongyun Zhao, Li Zhang
A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer. Cancer medicine 6 (5) (2017)